🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

Recruitingn/aAges 18 Years - anyAllOkuvision GmbH
NCT07548944 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease * Current treatment with TES using the OkuStim® System within the intended purpose * Subjective perception of short-term effects after TES treatment * Ability and willingness to give informed consent Exclusion Criteria: * Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation * Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments * Simultaneous participation in other clinical studies that could influence the results of the study * Severe comorbidities that could compromise patient safety or study conduct
💊

What it tests

  • Transcorneal Electrical Stimulation using the OkuStim System
📍

Where

1 site
Augenzentrum Frankfurt Prof. Koch GmbH
Frankfurt am Main, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy